Reducing the most harmful drinking patterns could make a meaningful difference for patients. In a linked commentary, also published in The Lancet, academics from the US said: The importance of evaluating GLP-1 therapies as new therapeutic options for alcohol use disorder cannot be overstated, Should forthcoming studies confirm efficacy of GLP-1 therapies for alcohol use disorder across a broad range of populations and settings, public health implications could be substantial a possibility that deserves celebration. Commenting on the study, Dr Marie Spreckley, research programme manager at the University of Cambridge, said: Overall, this study provides encouraging early evidence for a potential new treatment approach for people with co-occurring obesity and alcohol use disorder, but larger and longer-term trials in more diverse populations are needed before this can inform routine clinical practice. Matt Field, professor of psychology at the University of Sheffield, said: This well-conducted trial showed that 26 weeks of semaglutide treatment led to a marked reduction in the frequency of heavy drinking among people with alcohol use disorder who were also obese
Compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan), with pricing flat across all dose levelsyour dose may increase without price changes
Its a reliable source of information that can help identify patterns over time
Prendre une pilule ne rglera pas notre dsquilibre entre ce que lon mange et lactivit que lon fait , dplore le Dr Lau
